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High-Density Lipoprotein and Coronary Heart Disease
Current and Future Therapies
Pradeep Natarajan, MD,* Kausik K. Ray, MD,‡ Christopher P. Cannon, MD*†
Boston, Massachusetts; and Cambridge, England
Coronary heart disease remains a major cause of worldwide morbidity and mortality despite therapeutic ad-
vances that control many risk factors such as low-density lipoprotein cholesterol to levels lower than previously
possible. Population studies have consistently demonstrated an inverse association between high-density li-
poprotein cholesterol (HDL-C) levels with the risk of coronary heart disease. As a result, HDL-C is gaining increas-
ing interest as a therapeutic target. In this review, we explore the protective mechanisms of HDL and how cur-
rent and future therapies harness these beneficial properties. We offer a biological framework to understand
treatment strategies as well as their resultant successes and failures to guide management and future direc-
tions. At present, raising HDL-C level holds great promise, on the basis of epidemiology and initial trials, but we
await the outcomes of the many large clinical outcomes trials currently under way to define the clinical role of
older and novel therapies to raise HDL-C level. (J Am Coll Cardiol 2010;55:1283–99) © 2010 by the American
College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.01.008C
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iurrently, our therapy for lipid modification for atheroscle-
osis treatment and prevention focuses on lowering low-
ensity lipoprotein cholesterol (LDL-C). Lipid-lowering
reatment directed at LDL-C with standard doses of
-hydroxy-3-methylglutaryl coenzyme A reductase inhibi-
ors (“statins”) has resulted in a relative risk reduction of
ne-third in major vascular events as compared with placebo
1). In patients at very high risk for vascular events, intensive
ipid-lowering has been shown to be beneficial compared
ith standard therapy (2–4). However, despite such notable
rogress, cardiovascular disease continues to be the leading
ause of death and disease worldwide. As a result, novel
trategies to address this residual risk have been sought.
The Framingham Heart Study in the 1980s demon-
trated that the risk of coronary heart disease (CHD) was
ignificantly lower among persons with higher levels of
igh-density lipoprotein cholesterol (HDL-C) (normal
ange 40 to 60 mg/dl) (5). A number of studies have
upported this inverse correlation between HDL-C and
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010, accepted January 4, 2010.HD (5–9); hence, HDL-C has quickly evolved as one of
he “traditional” risk factors used by clinicians to predict risk
f incident CHD (4). An estimated 1 mg/dl higher
DL-C is associated with a 2% lower risk of CHD for men
nd a 3% lower risk for women (10). Current guidelines
ecommend lowering non–HDL-C as a secondary target
fter LDL-C lowering in recognition of the atherogenicity
f lipoproteins associated with hypertriglyceridemia (4).
raditional lipid-lowering therapy appears to lower LDL-C
nd non–HDL-C similarly, and these parameters are often
ot distinguished in trials. Even after LDL-C is aggressively
ontrolled to very low levels with statin therapy, low
DL-C still remains a significant cardiovascular risk factor
11,12). As a result, there has been increasing interest in
DL-C as a therapeutic target (13).
revalence
he prevalence of low levels of HDL-C (e.g., 40 mg/dl)
aries geographically (14) and is particularly high in Latin
merican countries, where the prevalence is as high as 46%
n men (15). Over a 7-year period, this prevalence has
ontinued to rise in Mexico by 2% to 3% (16). Approxi-
ately 25% of men in the United Kingdom have low levels
f HDL-C (17). A more recent Pan-European survey
uggests that the prevalence throughout Europe is similar to
hat in the U.S., with low HDL-C levels in nearly one-half
f the Dutch (18). Although a significant number in China
ave low HDL-C levels, the prevalence is much lower than
n North America, with 7% of men and 2% of women
aving low levels (19). In the international study evaluating
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HDL Therapies March 30, 2010:1283–99risk factors for acute myocardial
infarction known as the INTER-
HEART study, it was recently
shown that there is specifically a
higher prevalence of low HDL-C
levels in South Asians compared
with other Asians (20).
Biological Role of High-
Density Lipoprotein (HDL)
The equilibrium between athero-
genic lipoproteins, such as low-
density lipoprotein (LDL), and
antiatherogenic HDL can affect
endothelial dysfunction and in-
flammation (21). In the face of
elevated LDL-C levels, HDL-C
appears to progressively protect
against atherosclerosis (21).
Circulating HDL particles are
greatly heterogeneous with a very
complex metabolic profile (Table 1).
The various HDL subclasses vary
n quantitative and qualitative content of lipids, apolipopro-
eins, enzymes, and lipid transfer proteins, resulting in
ifferences in shape, density, size, charge, and antigenicity.
iscoid HDL particles are small, lipid-poor particles made
f apolipoprotein in a monolayer of phospholipids and free
holesterol (21–23). Spherical HDL particles are larger, are
ade from discoid HDL, and contain a hydrophobic core of
holesterol esters (21–23).
Reverse cholesterol transport, the process of transporting
xcess cholesterol from the arterial wall’s foam macrophages
o the liver, bile, and feces is one of HDL’s antiatherogenic
roperties (24,25) (Fig. 1). Lipid-free HDL, or apolipopro-
ein A-I, mediates this through the adenosine triphosphate
ATP)-cassette binding transporter (ABC) A1. Then ester-
fication of HDL-C by lecithin-cholesterol acyltransferase
LCAT) generates more mature HDL particles, including
mall, dense spherical HDL3 and large, less dense spherical
DL2 (22,24). These mature HDL particles may induce
urther cholesterol efflux through ABCG1 and ABCG4
21,24,26). HDL-C measures the cholesterol content of
ascent HDL, HDL2, and HDL3 particles and is, there-
ore, a crude marker of reverse cholesterol transport. The
Abbreviations
and Acronyms
ABC  ATP-binding
cassette transporter
ACAT  acyl-coenzyme A
cholesterol acyltransferase
ATP  adenosine
triphosphate
CETP  cholesterol ester
transfer protein
CHD  coronary heart
disease
HDL-C  high-density
lipoprotein cholesterol
LCAT  lecithin-cholesterol
acyltransferase
LDL-C  low-density
lipoprotein cholesterol
PPAR  peroxisome
proliferator-activated
receptor
VLDL  very low-density
lipoprotein
hysical Properties of HDL ParticlesTable 1 Physical Properties of HDL Particles
Particle Diameter, nm Density, g/ml
Discoid HDL 8 —
Spherical HDL3 8–9 1.125–1.21
Spherical HDL2 9–10 1.063–1.125
iscoid high-density lipoprotein (HDL) is quickly degraded when extracted from plasma. As a result,
hen human HDL is processed through density gradient ultracentrifugation, the predominanta
ubfractions include HDL2 and HDL3. HDL3 is smaller and denser, and is relatively protein rich and
ipid poor (21–23).maller HDL3 particles more efficiently promote cholesterol
fflux through the ABCA1 pathway than do their larger
ounterparts, but they are equally as effective through the
BCG1 pathway (27–29).
After cholesterol efflux from the plaque, reverse cholesterol
ransport is completed by transport back to the liver. Through
he scavenger receptor B1, hepatocytes and steroid-producing
ells can uptake these mature HDL particles (25,30). Further-
ore, cholesterol esters from these particles may be trans-
erred to apolipoprotein B-containing particles, such as
DL or very low-density lipoprotein (VLDL), through the
holesterol ester transfer protein (CETP) (22,24,25). He-
atic LDL receptors can then scavenge these apolipoprotein
–containing particles enriched with cholesterol esters,
urther contributing to reverse cholesterol transport (25).
he subsequent HDL particle enriched with triglycerides
ay regenerate small HDL particles through hydrolysis
rom hepatic lipase (21,24,25).
In addition to HDL protecting against atherosclerosis
hrough reverse cholesterol transport, HDL’s antioxidative ac-
ivity further protects against atherosclerosis (21,31) (Table 2).
polipoprotein A-I is a major factor in this process (31). In
ddition to HDL-C esterification, LCAT can also hydrolyze
xidized phospholipids of LDL (22,31,32).
For monocytes to gain entry into the subendothelial space
o promote atherosclerosis, their circulation must be ar-
ested, which is accomplished by binding to adhesion
olecules in the blood vessel wall (33,34). Expression of
hese adhesion molecules depends on inflammatory cyto-
ines and vascular injury, and is up-regulated in atheroscle-
osis (35–38). Animal models have demonstrated that HDL
nhibits the expression of adhesion molecules (39,40). HDL
an also directly inhibit the migration of these monocytes
nto the subendothelial space (41). In the endothelium,
itric oxide protects against inflammation and activation
42). HDL promotes vasoprotection by enhancing nitric
xide synthase and thereby increasing the production of
itric oxide (42,43). In addition to protection against
latelet activation through endothelial protection, HDL
nhibits the coagulation cascade through serine protease
rotein C, which inactivates factors Va and VIIa (42,44–46).
Dysfunctional” HDL
tructural and functional changes accompany HDL in the
etting of acute or chronic inflammation. Leukocyte myelo-
eroxidase may alter the function of normally atheroprotec-
ive molecules into so-called “dysfunctional” HDL with
roinflammatory properties (47). During inflammation,
DL-C levels can be reduced because of increased HDL
atabolism, decreased apolipoprotein A-I synthesis, and
isplacement of apolipoprotein A-I from HDL with serum
myloid A, an acute-phase protein (48,49). Additionally,
latelet-activating acetylhydrolase and LCAT can become
ysfunctional or diminished during inflammation, and
mong persons with low HDL-C levels such as those with
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March 30, 2010:1283–99 HDL Therapiesype 2 diabetes mellitus and CHD (31,41,50–52). Further-
ore, in the metabolic syndrome, hypertriglyceridemic
tates and the acute-phase response, largely through CETP,
nrich the triglyceride content of HDL-C (48,53). In turn,
riglyceride-rich HDL-C particles result in a lowering of
Figure 1 Reverse Cholesterol Transport and Therapeutic Target
Reverse cholesterol transport is one of the primary antiatherogenic properties of h
through adenosine triphosphate-binding cassette transporters (ABC) as lecithin-cho
and HDL3 particles (22,24). Furthermore, cholesterol ester transfer protein (CETP)
HDL (22,24,25). Subsequently, these HDL particles are taken up by hepatocytes t
agents attempt to increase HDL-C levels by affecting different steps involved in re
CE  cholesterol ester; FC  free cholesterol; LDL  low-density lipoprotein; PL 
VLDL  very low-density lipoprotein.
roperties of HDLTable 2 Properties of HDL
Function Mechanism
Reverse cholesterol transport Cholesterol efflux through ABCA1, ABCG1,
ABCG4 (21,22,24–29)
LDL antioxidation Activation of LCAT (29,31,32)
Endothelial protection Inhibition of adhesion molecule expression
(39,40), prevention of monocyte
chemotaxis (41), nitric oxide synthase
stimulation (42,43)
Antiplatelet activity Protection against endothelial injury (42)
Anticoagulation Inhibition of factors Va and VIIa (44–46)f
BC  adenosine triphosphate-binding cassette transporter; HDL  high-density lipoprotein;
CAT  lecithin-cholesterol acyltransferase; LDL  low-density lipoprotein.irculating HDL-C levels through their inherent instability
nd subsequent degradation as well as through hydrolysis
rom hepatic lipase (53). Furthermore, triglyceride-rich
DL-C cannot be taken by hepatocytes through scavenger
eceptor B1 as readily, resulting in reduced efficacy of reverse
holesterol transport (53,54). Therefore, a combination of
etabolic abnormalities and inflammatory milieu may result
n “dysfunctional” HDL (31,55).
onpharmacological Interventions
bservational and interventional studies have assessed the
elationship between lifestyle factors and circulating
DL-C levels.
erobic exercise. In young adult women, moderate activity
as shown to significantly increase HDL-C over the course
f 6 months (56). In a population of men and women
anging from 50 to 65 years of age, however, an increased
nsity lipoprotein (HDL) (24,25). This efflux of cholesterol is largely facilitated
ol acyltransferase (LCAT) helps modify these particles into more mature HDL2
fers additional cholesterol esters from apolipoprotein B-containing particles to
scavenger receptor B1 (SRB1) (25,30). The various current pharmacologic
holesterol transport. ACAT  acyl-coenzyme A cholesterol acyltransferase;
pholipid; PPAR  peroxisome proliferator-activated receptor; TG  triglycerides;s
igh-de
lester
trans
hrough
verse c
phosrequency of exercise resulted in the highest HDL-C levels
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HDL Therapies March 30, 2010:1283–9957). Meanwhile, over the short term, such as within the
rst month of aerobic exercise, the anti-inflammatory ben-
fits of HDL predominate (58). For example, over the
ourse of only 3 weeks of exercise, although HDL-C levels
id not increase, HDL preferentially converted to an anti-
nflammatory state (58).
iet. The dietary consumption of saturated fats, unlike
olyunsaturated and monounsaturated fats, promotes ath-
rosclerosis (59). A high saturated fat diet has been shown
o diminish the ability of HDL to protect the endothelium
nd reduces vasoreactivity (60,61). In contrast, a high
olyunsaturated fat diet enhances these features (62). In
itro, HDL suppresses the chemokines that attract inflam-
atory cells to the vessel wall (63–65).
Purely “low fat” diets have been shown to decrease
DL-C to a similar degree as LDL-C is reduced. How-
ver, when unsaturated fat replaces saturated fat and trans-
ats, LDL-C decreases proportionally more, thereby de-
reasing the LDL-to-HDL ratio (62,66). Diets high in
onounsaturated fats, including olive oil and canola oil,
ave been shown to reduce LDL-C without adversely
ffecting HDL (67). Certain polyunsaturated fats, including
-3-polyunsaturated fatty acids, largely found in fish oil, can
levate levels of HDL-C, especially among persons with high
riglycerides (68,69). Grapeseed oil, a byproduct of winemak-
ng, that contains a mixture of polyunsaturated vegetable oils
ay increase HDL-C levels by nearly 13% (70).
Glycemic index measures how much a carbohydrate-
ontaining food increases blood sugar levels and is deter-
ined by fiber content, glucose content, and digestibility.
ata suggest that the carbohydrate quality, or glycemic
ndex, may affect HDL-C levels (71). For instance, the
avorable effect of low glycemic index foods on increases in
DL-C levels was observed in both the U.S. and Europe
72,73). In the Nurse’s Health Study, persons particularly
usceptible to insulin resistance had increases in their
DL-C when eating foods with low glycemic index (74).
eight loss. Obesity is the central abnormality that con-
ributes to the metabolic syndrome and is associated with
ow HDL-C and high triglyceride levels. Losing weight
hrough diet or aerobic exercise equally results in an increase
n HDL-C, without significant differences between the 2
trategies (75). The effect of weight loss from caloric
estriction and regular exercise is particularly beneficial for
verweight or obese men and women (76). In a meta-
nalysis, subjects actively losing weight initially experience a
eduction in HDL-C levels, but subjects at a stabilized,
educed weight have HDL-C levels inversely proportional
o their weight (77). This finding is consistent with the
bservation that lipoprotein lipase decreases with acute
aloric restriction but increases with weight loss, especially
hen the weight is stabilized (78,79). A sustained reduction
n weight can be achieved through various mechanisms, but
ll have similar favorable effects on HDL-C levels.
obacco cessation. The Framingham study group showedhat cigarette smoking accounted for a drop in HDL-C by cmg/dl in men and 6 mg/dl in women (80). A meta-
nalysis demonstrated that smokers generally have a 9%
ower HDL-C level and a 6% lower apolipoprotein A-I
evel compared with matched nonsmokers (81). This inverse
ssociation of cigarette smoking and HDL-C levels is dose
ependent (81–84). Increased CETP activity and the re-
ultant transfer of cholesterol esters from HDL to apoli-
oprotein B-containing particles mediate tobacco smoking’s
therogenic lipoprotein changes (85,86). Furthermore, in a
eta-analysis of 27 studies, it was observed that when
articipants quit smoking tobacco, their HDL-C levels rose
y 4 mg/dl without a significant effect on total cholesterol,
DL-C, or triglyceride levels (87). Additionally, smoking
essation results in an increase in apolipoprotein A-I (88).
hese favorable effects on the lipid profile can be seen as
arly as 30 days after quitting smoking (89).
lcohol. While heavy alcohol intake is associated with
ncreased all-cause mortality and cardiovascular-related
ortality (90–94), moderate alcohol intake appears to have
protective effect on CHD (95–99). Part of this protection
ay be mediated by an associated increase in HDL-C
100–103). An increase in both the HDL2 and HDL3
ubfractions, but with relatively larger increase in HDL2, is
bserved with moderate alcohol consumption (103,104). A
ystematic review showed that all forms of alcohol (e.g.,
eer, wine, and spirits) had a favorable cardioprotective
ffect (105). However, data suggest that wine consumption
rovides more cardioprotection (106). Some of this additive
enefit may be from “flavonoids” such as resveritrol that act
s lipoprotein antioxidants (107). The recommendation of
lcohol consumption for cardiovascular protection is limited
y the potential for abuse, dependence, and caloric intake.
harmacological Interventions
arious randomized controlled trials have evaluated the
fficacy and safety of pharmacologically modifying HDL
Table 3).
tatins. The reduction of LDL-C with statins has a
ositive effect on the occurrence of cardiovascular events
108–112). A decrease in LDL-C levels from statin therapy
s associated with a decrease in the progression of athero-
clerosis (113–115). Increases in HDL-C between 5% and
5% have been reported with statin-mediated therapy, with
n average increase of 9% (108,110,111,116). However,
he data regarding the clinical significance of this are
nclear. The statin-induced HDL-C effects are relatively
mall compared with the LDL-C effects, so the effects of
tatins on HDL-C are likely to be small. Nevertheless, a
ecent meta-analysis of statin therapy demonstrated that, in
atients with CHD in whom LDL-C levels are aggressively
educed to 87.5 mg/dl, an increase in HDL-C by 7.5% is
ndependently associated with a regression in coronary
therosclerosis (116). Statins also promote the formation of
more favorable HDL subfraction profile by creating moreholesterol-rich HDL particles, perhaps through the reduc-
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March 30, 2010:1283–99 HDL Therapiesion of cholesterol transfer from HDL (117–120). That may
ccur through the reduction in available apolipoprotein
-containing atherogenic particles to accept cholesterol
sters and down-regulation of CETP expression (121,122).
iacin. Currently, niacin (vitamin B3) is the most effective
vailable pharmacologic means to raise HDL-C levels.
nterest in niacin developed 50 years ago when it was
oted to decrease total cholesterol, lower LDL-C, and
aise HDL-C (123,124). Niacin increases HDL-C levels by
5% to 35% with a nonlinear dose-dependent response
125–129). Therefore, the majority of the beneficial effects
f niacin occurs at doses of 1 to 1.5 g per day (126,129).
Niacin accomplishes this effect on HDL through multi-
le mechanisms. It selectively inhibits hepatic clearance of
DL’s apolipoprotein A-I and not the cholesterol esters
130,131). As a result, the cholesterol-deficient apolipopro-
ein A-I–containing HDL particles are recycled into the
irculation and freed for further reverse cholesterol transport
130,132). Furthermore, niacin directly inhibits the transfer
f cholesterol esters through CTEP from HDL to apoli-
oprotein B-containing particles by directly inhibiting
TEP activity as well as by reducing the hepatic synthesis
harmacotherapy and Effects on HDL-CTable 3 Pharmacotherapy and Effects on HDL-C
Medication Class Mechanism
Statins Reduced cholesterol transfer from HDL through
decreased ApoB-containing particles and
reduced CETP expression (117–122)
Niacin Inhibition of hepatic clearance of ApoA-I, CETP
inhibition, reduced CETP synthesis, reduced
adipose tissue lipolysis, ABCA1 transcription
promotion, hepatic lipase inhibition
(130–136)
CDP (1
Isch
Pre
ARB
Fibrates PPAR agonism resulting in ABCA1
up-regulation and synthesis, and ApoA-I
transcription (122,162–167)
Helsin
BIP
Thiazolidinediones PPAR agonism resulting in cellular
differentiation in vascular tissue and
adipocytes (190)
PROAC
PER
Glitazars PPAR and PPAR agonism (199–201) Kenda
CETP inhibitors CETP inhibition (122,212–219) ILLUM
RAD
ACAT inhibitors ACAT-1 and ACAT-2 inhibition reducing
intracellular cholesterol esterification
(247,248)
ACTIVA
Recombinant
HDL infusion
Reverse cholesterol transport (259), increased
nitric oxide bioavailability (257,258)
ERASE
ApoA-I Milano
infusion
Antioxidation from free cysteine residues
(264–266)
Nissen
ApoA-I mimetics Saponification by amphipathic alpha-helices
(273,274), ABCA1-dependent reverse
cholesterol transport (273), antioxidation
(281)
ApoA-I up-regulators Promotion of ApoA-I transcription (287)
There are several phase III trials with statins targeted specifically to low-density lipoprotein chol
HDL-C) levels after infusions were not routinely measured in the ERASE study or in apolipoprotei
imetic, 4F, and the Apo A-I up-regulator, RVX-208 (281,288,289).
ACAT  acyl-coenzyme A cholesterol acyltransferase; CETP  cholesterol ester transfer proteinf CTEP (133). Niacin also targets this pathway by reduc- cng the lipolysis in adipose tissue. That reduces the release of
ree fatty acids into plasma, with a consequent decrease in
ree fatty acid uptake by the liver that leads to a secondary
ecrease in hepatic triglyceride synthesis. The resulting
ecrease in concentration of plasma VLDL results in a
eduction in the transfer of cholesteryl esters from HDL to
LDL, and hence an increase in concentration of HDL-C
134). At a more local level, through the cyclic adenosine
onophosphate/protein kinase A secondary messengers,
iacin promotes the transcription of ABCA1 to provide
DL particles with targets for reverse cholesterol transport
135). Moreover, niacin tends to promote the formation of
DL2 through its inhibition of hepatic lipase (136).
The CDP (Coronary Drug Project) evaluated the effect
f niacin on 8,341 men with a history of myocardial
nfarction during 1966 to 1975 (137). Over a 5-year
ollow-up period, the incidence of nonfatal reinfarction was
educed by 27%. Even more compelling is that 15 years
ater, niacin contributed to a significant decrease in all-cause
ortality by 9% (138).
Additional clinical studies of niacin have typically been in
he setting of combination therapy. When combined with
Phase II/III Trials HDL-C Increase Ongoing Large Trials
* 5%–15% —
ATS (139), CLAS (141), Stockholm
Heart Disease Secondary
Study (143), ARBITER 2 (154),
-HALTS (155)
15%–35% AIM-HIGH (156);
HPS2-THRIVE (157)
rt Study (168), VA-HIT (169),
FIELD (173)
10%–15% ACCORD (188)
193), CHICAGO (194),
E (195), RECORD (197)
5%–10% —
. (205) 15%–30% Aleglitazar (211)
(228), ILLUSTRATE (232),
1 (234), RADIANCE2 (235)
40%–130% dal-OUTCOMES (241),
dal-VESSEL (242),
dal-PLAQUE (243),
DEFINE (246)
3), CAPTIVATE (254) 0%–5% —
† —
(270) † —
— ‡ —
— ‡ —
(LDL-C) lowering, which is outside the scope of this review. †High-density lipoprotein cholesterol
A-I trials (258,268). ‡Only phase I safety data in humans are currently available for the Apo A-I
 peroxisome proliferator-activated receptor; other abbreviations as in Table 2.37), F
aemic
vention
ITER 6
ki Hea
(171),
TIVE (
ISCOP
ll et al
INATE
IANCE
TE (25
(260)
et al.
esterol
n (Apo)olestipol, a bile-acid sequestrant, in the FATS (Familial
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HDL Therapies March 30, 2010:1283–99therosclerosis Treatment Study), HDL-C increased by
3%, with angiographic atherosclerotic regression in 39%
nd a 73% reduction in CHD rates over a 2.5-year
ollow-up period (139). After 10 years of niacin combined
ith both colestipol and lovastatin, there was an 18.5%
bsolute risk reduction in all-cause mortality (140). The
LAS (Cholesterol-Lowering Atherosclerosis Study) also
valuated the effect of combining colestipol with niacin in
62 men who had prior coronary artery bypass graft surgery,
nd demonstrated an HDL-C increase by 37%, with an-
iographic regression of atherosclerosis of 16% at 2 years
nd 18% at 4 years (141,142).
Combining niacin with a fibrate has also been shown to
e effective. In the Stockholm Ischaemic Heart Disease
econdary Prevention Study, 554 post-myocardial infarc-
ion patients were randomly assigned to placebo or to a
ombination of niacin and clofibrate, and those in the active
reatment arm experienced a 26% reduction in all-cause
ortality and a 36% reduction in CHD mortality (143).
owever, this beneficial effect was more correlated with the
xtent of reduction in serum triglyceride levels. When
xamined among patients with CHD and low HDL-C
evels, triple therapy with cholestyramine, a bile-acid se-
uestrant, gemfibrozil, and niacin resulted in a 36% increase
n HDL-C and a 13.7% reduction in CHD events (144).
A common limiting side effect of niacin is facial pruritis
nd flushing caused by prostaglandin-mediated vasodilation
hrough the G-coupled protein receptor, GPR109A
132,145). This pathway additionally, at least partially,
ediates the niacin-mediated antilipolytic effects in murine
odels (145). Interestingly, flushing may be a marker of an
ncreased lipid response to niacin (146). Paradoxically, the
resence of flushing as a surrogate for niacin’s efficacy may
romote adherence through appropriate patient education.
eanwhile, these flushing symptoms can be ameliorated
ith the once-daily extended-release formulation, which is
qually as efficacious as the immediate-release formulation
147). This flushing can also be addressed by taking aspirin
0 min before dosing and by avoiding spicy foods. Niacin in
ts immediate-release or extended-release form is safe and
olerable for diabetic patients as well (148). However, higher
oses of niacin resulted in a slight worsening of glycemic
ontrol (p  0.048) in the ADVENT (Assessment of
iabetes Control and Evaluation of the Efficacy of Niaspan
rial) of type 2 diabetic patients randomly assigned to
iacin or placebo (148). When niacin is given at doses 2.5
, it is associated with a 4% to 5% increase in fingerstick
lucose levels and may or may not have effects on hemo-
lobin A1c, and these effects on hemoglobin A1c may be
ransient only during uptitration of doses (149). Guidelines
rom the National Cholesterol Education Program, Amer-
can Heart Association, American Diabetes Association,
nd National Lipid Association all consider niacin at doses
2 g daily safe for diabetic patients to manage dyslipidemia,
nd the cardiovascular benefits may outweigh the risks
14,150–152). Additionally, the National Lipid Association hurther asserts that patients with impaired glucose tolerance
ithout overt diabetes mellitus (e.g., fasting glucose 110 to
25) can safely take niacin with careful monitoring of glycemic
ontrol, similar to that for diabetic patients when niacin
herapy is initiated (152).
Both formulations have been evaluated in combination
ith statins. In the HATS (HDL-Atherosclerosis Treat-
ent Study), patients with CHD, HDL-C35 mg/dl, and
DL-C 145 mg/dl treated with both simvastatin and
xtended-release niacin had an increase in HDL-C levels by
6%, slight regression in proximal coronary artery stenosis
y angiography, and a 90% reduction in CHD events versus
ual placebo, although this represented 9 versus 1 events
153). In the ARBITER 2 (Arterial Biology for the Inves-
igation of Treatment Effects of Reducing Cholesterol 2)
rial, extended-release niacin was given to patients with
HD, HDL-C 45 mg/dl, and LDL-C 120 mg/dl who
ere already receiving statin therapy (154). This treatment
esulted in a 21% increase in HDL-C and a trend toward a
ecrease in the progression of carotid intima media thick-
ess as assessed by ultrasonography over a 1-year follow-up
eriod (154). The follow-up study, ARBITER 6 (HDL and
DL Treatment Strategies in Atherosclerosis), was de-
igned to compare the effects of HDL-C–lowering therapy
ith extended-release niacin versus additional LDL-C–
owering therapy with ezetimibe on atherosclerosis progres-
ion in patients already receiving statin therapy (155). This
rial was stopped early in 2009 with just 208 evaluable
atients when it was seen that patients receiving niacin had
significant reduction in carotid-intima media thickness at
oth 8 months and 14 months (155).
Currently, the AIM-HIGH (Atherothrombosis Inter-
ention in Metabolic Syndrome with Low HDL/High
riglycerides and Impact on Global Health Outcomes)
tudy has enrolled 3,300 patients with CHD and evidence
f the metabolic syndrome with HDL-C 40 mg/dl and
riglycerides 150 mg/dl not already given statin therapy
156). In this U.S.–Canadian, multicenter, randomized,
ouble-blind, parallel-group, controlled clinical trial, pa-
ients have been randomly allocated to therapy with simva-
tatin alone or simvastatin and extended-release niacin and
re being evaluated over a 5-year period to better define the
dditive effect of HDL-raising therapies. Another trial, the
PS2-THRIVE (Heart Protection Study 2 Treatment on
DL to Reduce the Incidence of Vascular Events) is
ecruiting 25,000 patients with a history of CHD, stroke, or
eripheral arterial disease and randomizing them to placebo
r a new tablet containing extended-release niacin plus a
pecific blocker of prostaglandin D2, called laropiprant, to
revent the flushing associated with niacin (157).
ibrates. Fibrates are peroxisome proliferator-activated re-
eptor (PPAR)- agonists that lower LDL-C by 10% to
0%, lower triglycerides by 25% to 45%, and increase
DL-C modestly by 10% to 15% (158–161). Through the
ctivation of PPAR, ABCA1 is up-regulated as well as
epatic HDL synthesis (162,163). The HDL production is
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March 30, 2010:1283–99 HDL Therapiesargely mediated through PPAR’s stimulation of the apo-
ipoprotein A-I gene’s promoter (164–166). PPAR ago-
ism may also decrease CETP gene expression, resulting in
ower levels of plasma CETP (122). Additionally, by reduc-
ng triglyceride-rich lipoproteins available to accept choles-
erol esters, HDL-C levels are boosted (122,167).
In the Helsinki Heart study, 4,081 healthy men without
HD with non–HDL-C 200 mg/dl were randomly
ssigned to gemfibrozil versus placebo (168). LDL-C de-
reased by 11%, triglycerides decreased by 35%, and
DL-C increased by 11%. Although the more pronounced
ffect was on triglycerides, the 34% reduction in CHD
vents was significantly associated with both LDL-C low-
ring and HDL-C elevation. The VA-HIT (Veterans
ffairs High-Density Lipoprotein Cholesterol Intervention
rial) evaluated patients with CHD, LDL-C 140 mg/dl,
riglycerides 300 mg/dl, and HDL-C 40 mg/dl on
emfibrozil (160). LDL-C levels did not differ significantly
etween the study groups over the 5-year study period, so
he 22% reduction in CHD events was attributed to the 6%
ncrease in HDL-C in a subsequent multivariable analysis
160,169). It was the first trial that demonstrated a relation-
hip between HDL-C increase and CHD event reduction
n patients with moderate LDL-C levels. Another analysis
f the VA-HIT study demonstrated that gemfibrozil ther-
py for patients with CHD and low HDL-C was cost
ffective in terms of the cost of quality-adjusted life-years
aved (170).
The effects of the fibrates on coronary events have been
ariable. Although bezafibrate therapy in patients with
HD and low HDL-C levels increases HDL-C by 18%,
here was only a trend toward the reduction of CHD events
n the BIP (Bezafibrate Infarction Protection) study (171).
16-year follow-up of this trial demonstrated that subjects
ith the highest HDL-C response to therapy had a signif-
cant reduction in the risk of death (172). In the FIELD
Fenofibrate Intervention and Event Lowering in Diabetes)
tudy, the authors studied the effect of fenofibrate therapy
n 9,795 randomized patients with type 2 diabetes mellitus
ot receiving statin therapy and with a total cholesterol level
f 251 mg/dl (173). However, fenofibrate did not signif-
cantly alter HDL-C levels but it did lower LDL-C and
riglyceride levels. There was no significant effect on total
oronary events, but a significant 24% reduction in nonfatal
yocardial infarction was observed. Overall, the FIELD
rial failed to demonstrate a significant benefit of an agent
hat predominantly reduces triglycerides in a high-risk
opulation. That may have resulted from a greater use of
pen-label statin therapy for subjects allocated to placebo.
tudies of clofibrate have been plagued with concerns
egarding potential safety (174–176).
The fibrates are primarily excreted renally, and there are
etrospective observational data suggesting that they may
esult in reversible worsening renal function in patients with
aseline renal impairment (177,178). In severe renal impair-
ent, the drug’s half-life is prolonged and is not dialyzable, znd there is concern regarding permanent renal dysfunction
n kidney transplant patients (177,179). Although the
echanism of inducing renal dysfunction is unclear, inter-
sting data propose that fibrates result in increased creati-
ine levels from increased creatinine production without an
ctual change in creatinine clearance (180). Renal function
n patients with severe nondialysis-dependent renal disease
hould be monitored during the initiation of fibrate therapy
or dyslipidemia, but fibrates are not contraindicated in
atients with baseline renal impairment.
Given the benefits of statin therapy for diabetic patients,
here is little evidence to recommend fibrates as an alternative
rst-line treatment to statins for the management of dyslipi-
emia among diabetic patients (181,182). The combination of
tatins and fibrates bears the risk of myotoxicity with an
ncidence of 0.12%, but there are some data suggesting the
enefits of combined statin and fibrate therapy, particularly for
iabetic patients (14,183–185). All fibrates have been associ-
ted with reports of creatinine kinase elevations and myopathy
hen given with statins, but that appears to occur more
requently with gemfibrozil than with fenofibrate (186). Gem-
brozil, more than fenofibrate, inhibits hepatic glucoronida-
ion of various statins, thereby preventing statin clearance and
ncreasing serum levels of statins in their active form (187).
he ACCORD (Action to Control Cardiovascular Risk in
iabetes) study is a large-scale trial that is currently prospec-
ively evaluating the safety and efficacy of the combination of
imvastatin and fenofibrate in managing dyslipidemia in type 2
iabetes (188).
hiazolidinediones. The insulin-sensitizing thiazolidinediones,
hich include pioglitazone and rosiglitazone, were approved
n the U.S. in the late 1990s for the treatment of type 2
iabetes mellitus. Troglitazone was also a member of this
lass but was withdrawn because of idiosyncratic liver injury
189). These agents are agonists of peroxisome proliferator-
ctivated receptor (PPAR)-, a nuclear receptor involved in
ellular differentiation, largely in vascular tissue and adipo-
ytes (190). Insulin resistance contributes to the metabolic
yndrome, which includes hyperglycemia, elevation in tri-
lycerides, and reductions in HDL-C levels. As a result,
nsulin-sensitizers such as thiazolidinediones were proposed
o not only correct dysglycemia but also to potentially
orrect lipid abnormalities (189).
A meta-analysis of 23 randomized trials demonstrated
hat pioglitazone increased HDL-C levels by 4.6 mg/dl and
hat rosiglitazone increased HDL-C levels by 2.7 mg/dl
191). However, unlike pioglitazone, rosiglitazone increased
DL-C and total cholesterol and did not decrease triglyc-
rides (191). Even in patients without overt diabetes mel-
itus but with evidence of insulin resistance, pioglitazone
ncreases HDL-C levels (192). The PROACTIVE (Pro-
pective Pioglitazone Clinical Trial in Macrovascular
vents) assessed the benefit of pioglitazone in a higher risk
opulation, type 2 diabetes with a hemoglobin A1c level
6.5%, and stable macrovascular disease (193). Pioglita-one increased HDL-C by 8.9% and decreased triglycerides
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HDL Therapies March 30, 2010:1283–99y 9.6% without a significant reduction in the primary end
oint but with a 16% reduction in the combined secondary
nd point of mortality and nonfatal myocardial infarction
nd stroke (193). Given the modest 0.6% decrease in
emoglobin A1c, many have speculated that part of the
linical benefits of these agents could be related to the
DL-C–raising benefits of these agents.
Pioglitazone has been recently tested against other oral
ypoglycemic agents, including glimepiride, a sulfonylurea
hat acts as an insulin secretagogue. In the CHICAGO
Carotid Intima Media Thickness in Atherosclerosis Using
ioglitazone) trial, type 2 diabetic patients treated with
ioglitazone had a decrease in the progression of carotid
ntima media thickness compared with type 2 diabetic
atients treated with glimepiride (194). More recently, the
ERISCOPE (Pioglitazone Effect on Regression of Intra-
ascular Sonographic Coronary Obstruction Prospective
valuation) study randomly allocated type 2 diabetic pa-
ients with CHD to pioglitazone or glimepiride (195).
atients treated with pioglitazone had a 4.6 mg/dl increase
n HDL-C levels and a decrease in CHD progression as
valuated by intravascular ultrasonography (195).
The effects of pioglitazone may not extend to thiazo-
idinediones, in general. Rosiglitazone does not result in the
ame favorable lipid profile (191). Furthermore, a recent
eta-analysis suggested that rosiglitazone treatment results
n a significant risk of myocardial infarction (196). How-
ver, in the large, randomized RECORD (Rosiglitazone
valuated for Cardiac Outcomes and Regulation of Gly-
aemia in Diabetes) trial, an interim analysis subsequently
howed no difference in myocardial infarction or cardiovas-
ular deaths (197). A meta-analysis of pioglitazone, largely
nvolving the PROACTIVE trial, demonstrated a decrease
n mortality, myocardial infarction, or stroke (198). With
he currently available data, this class is generally not used
or HDL modification.
litazars. A new class of agents called “glitazars” with
ombined PPAR- and PPAR- agonism is being evalu-
ted (199–201). These drugs would theoretically combine
he lipid benefits of PPAR activation with the insulin-
ensitizing effects of PPAR activation to optimally treat
he metabolic syndrome.
Ragaglitazar increased HDL-C by 31%, decreased triglycerides
y 62%, and decreased hemoglobin A1c by 1.3%, but the
dverse events of edema, anemia, and leukopenia have
rawn concern (202,203). Muraglitazar increases HDL-C
y as much as 16% in type 2 diabetic patients, but, as with
agaglitazar and the thiazolidinediones, weight gain and
dema were more common with muraglitazar therapy
204,205). An analysis of muraglitazar’s phase 2 and 3 data
evealed an increase in risk of death, cardiovascular events,
nd congestive heart failure associated with muraglitazar
206). Tesaglitazar, a third agent in this drug class, can
ncrease HDL-C by 13% (207–209). Recently, a phase 2
rial of aleglitazar was shown to increase HDL-C by 20%
nd also decrease hemoglobin A1c in a dose-dependent ianner, with an increase in edema but not congestive heart
ailure or myocardial infarction (210). As a result, a phase 3
tudy of aleglitazar in type 2 diabetic patients with a recent
cute coronary syndrome has been announced (211).
ETP inhibitors. Humans with CETP deficiency due to
olecular defects in the CETP gene have markedly elevated
lasma levels of HDL-C and apolipoprotein A-I (212,213).
tudies regarding the association of lower CETP levels and
therosclerosis are mixed, but patients with CETP defi-
iency and higher HDL-C levels tend to have lower rates of
therosclerotic disease (214–217). There was initial concern
hat the larger, cholesterol-rich HDL particles formed
hrough CETP inhibition would not as efficiently allow for
everse cholesterol transport (218). In response, a study
howed that these larger particles promote cholesterol efflux
hrough the ABCG transporter (219). Such observations
ed to the concept that pharmacological CETP inhibition
ight favorably increase HDL-C levels (122).
Animal models of CETP inhibitors using a variety of
ifferent pharmacological strategies have resulted in an increase
n HDL-C and an attenuation of atherosclerosis (220–226).
arly small studies of torcetrapib, a direct CETP inhibitor, in
ealthy subjects and patients with HDL-C 40 mg/dl dem-
nstrated significant increases in HDL-C levels of 50% to 60%
218,227). Torcetrapib was evaluated on a much larger scale
hrough the ILLUMINATE (Investigation of Lipid Level
anagement to Understand its Impact in Atherosclerotic
vents) trial (228). In that trial, 15,067 patients with a history
f cardiovascular disease or type 2 diabetes mellitus receiving
torvastatin were randomly assigned to torcetrapib or placebo.
atients receiving torcetrapib experienced a 72.1% increase in
DL-C, a 24.9% decrease in LDL-C, and a 9% decrease in
riglycerides over 1 year. However, the ILLUMINATE trial
as prematurely terminated because of an increase in cardio-
ascular events (hazard ratio: 1.25; 95% confidence interval:
.09 to 1.44) and all-cause mortality (hazard ratio: 1.58; 95%
onfidence interval: 1.14 to 2.19). Off-target toxic effects
ncluding hyperaldosteronism as reflected by the observed
ypokalemia, hypernatremia, and increase in systolic blood
ressure by a median of 5.4 mm Hg specific to the molecule
tself may have been the culprits (228,229). Additionally, there
s speculation that the HDL particles formed by torcetrapib
ay not participate in reverse cholesterol transport and other
ardioprotective qualities, but recent data suggest that these
articles do participate in reverse cholesterol transport
229–231).
The ILLUSTRATE (Investigation of Lipid Level Man-
gement Using Coronary Ultrasound to Assess Reduction
f Atherosclerosis by CETP Inhibition and HDL Eleva-
ion) study concurrently did not show an effect of torce-
rapib on coronary atherosclerosis (232). A post-hoc analysis
uggested that patients who experienced the highest level of
DL-C increase did have some regression of coronary
therosclerosis (233). Patients with familial hypercholester-
lemia treated with torcetrapib in the RADIANCE1 (Rat-
ng Atherosclerotic Disease Change by Imaging With a
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March 30, 2010:1283–99 HDL Therapiesew CETP Inhibitor 1) study did not demonstrate a
hange in carotid intima media thickness despite a 55.5%
ncrease in HDL-C (234). There was also progression of
isease in the common carotid segment, raising the concern
f a directly toxic effect of torcetrapib on the endothelium
229,234). In the RADIANCE2 trial, patients with mixed
yslipidemia also had a similar increase in HDL-C, without
n effect on carotid intima media thickness (235). Similar to
n the ILLUMINATE trial, torcetrapib was associated with
small increase in blood pressure in the ILLUSTRATE,
ADIANCE1, and RADIANCE2 studies (232,234,235).
Dalcetrapib (also known as R1658, JTT-705, and
O460731) is another CETP inhibitor (236). A phase 2
rial involving healthy subjects demonstrated a 34% increase
n HDL-C (237). Another phase 2 trial involving patients
ith dyslipidemia on pravastatin therapy showed an associ-
ted 28% increase in HDL-C with dalcetrapib (238).
either study had an increase in blood pressure or cardio-
ascular adverse events, as seen in the torcetrapib trials
237–239). In vitro, dalcetrapib does not activate the renin-
ngiotensin-aldosterone pathway (240). Currently, the
hase 3 dal-OUTCOMES trial is recruiting 15,600
atients with recent acute coronary syndromes to further
tudy dalcetrapib’s effect on cardiovascular morbidity and
ortality as well as its safety profile (241). Also, the phase
b dal-VESSEL study will further evaluate dalcetrapib’s
avorable effect on endothelial function in hypercholester-
lemic patients with a low baseline HDL-C level (242).
nd the phase 2b dal-PLAQUE study plans to characterize
ts effects on atherosclerotic plaque with magnetic resonance
maging and positron emission tomography/computed to-
ography (243).
Anacetrapib (also known as MK-0859) is a novel, potent
ETP inhibitor also being studied. A phase 1 trial involving
ealthy subjects documented an increase in HDL-C up to
29% without an effect on blood pressure (244). Recently, a
hase 2 trial showed that 589 patients with dyslipidemia
eceiving atorvastatin randomly assigned to anacetrapib had
130% increase in their HDL-C levels and a decrease of
40% in their LDL-C levels without an effect on blood
ressure (245). The DEFINE (Efficacy and Tolerability of
ETP Inhibition With Anacetrapib) trial has recruited
,623 patients with CHD already receiving statin therapy
or an anacetrapib phase 3 safety trial, and a larger outcomes
tudy is planned (246).
CAT inhibitors. A target for treating atherosclerosis has
een the inhibition of acyl-coenzyme A cholesterol acyl-
ransferase (ACAT), which esterifies cholesterol in a range
f tissues (247,248). Theoretically ACAT, specifically
CAT-1, inhibition would slow the progression of foam
acrophage cells in theory (249). Subsequently, free cho-
esterol would be available for reverse cholesterol transport
250). ACAT-2, the other identified ACAT isoform, is
resent in the liver and intestine, so inhibition of this
nzyme would reduce LDL formation (251). cAvasimibe, a nonselective ACAT inhibitor, was assessed
n 639 randomized patients with CHD in the phase 2
-PLUS (Avasimibe and Progression of Lesions on Ultra-
ound) study (252). Unfortunately, avasimibe did not alter
DL-C levels, and it did not have an impact on coronary
therosclerosis as assessed by intravascular ultrasonogra-
hy (252). Pactimibe, another nonselective ACAT inhib-
tor, was evaluated by intravascular ultrasonography in
he ACTIVATE (ACAT Intravascular Atherosclerosis
reatment Evaluation) trial of 408 patients with CHD
253). Pactimibe resulted in a 5.4% (p  0.04) increase in
DL-C, but although there was no difference compared
ith placebo with respect to atherosclerosis progression,
econdary variables suggested that pactimibe limited athero-
clerosis regression compared with placebo (253). Further-
ore, the more recent CAPTIVATE (Carotid Atheroscle-
osis Progression Trial Investigating Vascular ACAT
nhibition Treatment Effects) evaluated the effects of pac-
imibe on carotid atherosclerosis using ultrasonography of
arotid intima media thickness in 892 patients with familial
therosclerosis (254). There was no change in HDL-C
evels, and although there was no change in maximum
arotid intima media thickness, but there was an increase in
ean carotid intima media thickness by 2.9% (p  0.05)
fter 1 year, and, notably, there was a significant absolute
isk increase of 2.1% of cardiovascular death, myocardial
nfarction, and stroke with pactimibe (254). Potential ex-
lanations for this proatherogenic effect of ACAT inhibi-
ion is that the accumulation of free cholesterol in macro-
hages results in ABCA1 degradation, limiting reverse
holesterol transport, and such free cholesterol abundance
auses cellular death, stimulating and intensifying the de-
elopment of atherosclerosis (255,256).
econstituted HDL infusion. Short-term infusions of
econstituted HDL have been a target of reverse cholesterol
ransport therapy. The HDL infusions also increase nitric
xide bioavailability for endothelial protection (257,258). In
small study of healthy subjects, these intravenous infusions
romoted reverse cholesterol transport (259).
On the basis of these data, the ERASE (Effect of rHDL
n Atherosclerosis–Safety and Efficacy) study randomly
ssigned 183 patients within 2 weeks of an acute coronary
yndrome to 4 weekly infusions of CSL-111, reconstituted
DL made of purified human apolipoprotein A-I and
oybean phosphatidylcholine (260). There was a nonsignif-
cant trend toward an improvement in coronary atheroma
olume when measured by intravascular ultrasonography,
ut the study was prematurely terminated because of a high
ncidence of liver function test abnormalities (260). None-
heless, there is some evidence that reconstituted HDL
nfusion promotes a favorable change in the quality of
oronary atheroma (260,261). In type 2 diabetic patients,
ecent data suggest that reconstituted HDL infusion not
nly suppresses the expression of inflammatory markers and
nhances reverse cholesterol efflux, but also augments gly-
emic control by increasing plasma insulin and activating
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HDL Therapies March 30, 2010:1283–99denosine monophosphate-activated protein kinase in skel-
tal muscle (262,263).
polipoprotein A-I Milano infusion. In 1980, a group in
ilano described 40 persons in a small village in northern
taly called Limone sul Garda who, despite very low
DL-C levels (10 to 30 mg/dl), had a reduced atheroscle-
otic disease burden and longer lives (264–266). This was
ttributed to an arginine to cysteine mutation at position
73 of apolipoprotein A-I, termed apolipoprotein A-I
ilano, allowing for disulfide bond dimer formation
264–266). Not all of the cysteine residues dimerize, and
he free thiol groups have antioxidant properties (267).
ecombinant apolipoprotein A-I Milano infusions in ani-
als demonstrated evidence of atherosclerosis regression,
hich can occur in as little as 48 h (268,269).
This therapy was piloted in humans when ETC-216,
ecombinant apolipoprotein A-I Milano complexed with
hospholipid, was randomly infused in 57 patients within 2
eeks of an acute coronary syndrome over 5 weekly treat-
ents (270). There was significant reduction in intravascu-
ar ultrasound-measured coronary atheroma burden with
TC-216, with 1 patient reported to have a significant rise
n transaminases (270). In a trial of 47 patients after an acute
oronary syndrome, recombinant apolipoprotein A-I Mi-
ano infusion was associated with reverse coronary remod-
ling whereby atheroma burden was reduced but luminal
ize was unchanged (271).
polipoprotein A-I mimetics. Apolipoprotein A-I is a
rotein with 243 amino acids and consists of a tandem
ssortment of amphipathic helices (272). Reverse choles-
erol transport by the ABCA1 pathway is mediated by the
etergent-like properties of these amphipathic helical seg-
ents (273,274).
The development of smaller peptides that retain such
ctivity began with the development of peptide mimetic
8A, consisting of 18 amino acids, which does not share
equence homology of apolipoprotein A-I but can form a
imilar amphipathic helix (275). Multiple modifications
ave been studied, but the most studied is 4F, which is a
imerized version of 18A with 2 phenylalanine substitutions
273,275–278).
An orally active 4F peptide made with D-amino acids,
-4F, given to mice decreases atherosclerotic lesions and
romotes reverse cholesterol transport (279,280). Phase I data
uggest that D-4F may be safe for humans with CHD, and
lthough it does not alter lipoprotein levels, it may improve the
DL anti-inflammatory index, but further clinical studies are
eeded to elucidate this significance (281).
Given concerns regarding possible cytotoxicity through
BCA1-independent lipid efflux, additional peptide mi-
etics have been engineered (282). Twenty-two amino acid
eptides based on domains of apolipoprotein A-I that have
higher affinity for ABCA1 have been shown to promote
holesterol efflux without cytopathic effects (282–284). Fur-
hermore, such domains are conserved across other apoli-
oproteins, and similarly designed peptides from apoli-oprotein E promote ABCA1-mediated reverse cholesterol
ransport (285). Recently, 5A, an asymmetric bihelical
eptide based on 2F, with 1 of the domains containing more
lanine residues and thereby reducing its helical content, has
een constructed to more closely reflect the combination of
ow- and high-affinity helices on apolipoprotein A-I (286).
he 5A peptide had increased ABCA1-dependent choles-
erol efflux and decreased hemolysis compared with its
arent compound (286).
The strategy of using peptide mimetics to treat athero-
clerotic disease is in its infancy but carries the potential to
reat disease through specific, endogenous pathways.
polipoprotein A-I up-regulators. Recently, a novel par-
icle called RVX-208 that increases the transcription of
polipoprotein A-I to promote reverse cholesterol transport
as been announced (287). This transport was facilitated
hrough the ABCA1, ABCG1, and SR-B1 pathways
hrough apolipoprotein A-I up-regulation (288). Phase I
ata from 24 healthy subjects have shown a dose-dependent
ncrease in apolipoprotein A-I, and thereby HDL function-
lity (288,289). Further data and investigation are needed to
ully examine the ability of small molecules up-regulating
polipoprotein A-I to impact the burden of atherosclerosis.
onclusions
here is overwhelming evidence that high levels of HDL-C
n nature are associated with a lower risk of CHD. Unlike
DL-C, the mechanisms controlling HDL-C are more
omplex. Lifestyle interventions are safe but only modestly
ncrease HDL-C. The best treatments available currently
re the niacin derivatives, although the newer CETP
nhibitors, apolipoprotein mimetics, and apolipoprotein up-
egulators hold much promise. The next 5 years should
rovide information on whether the flux or cycling of HDL
s more important than HDL-C levels and also whether we
hould target raising specific HDL subclasses rather than
DL-C itself.
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